Gail L. Brown

605 total citations
41 papers, 469 citations indexed

About

Gail L. Brown is a scholar working on Molecular Biology, Oncology and Hematology. According to data from OpenAlex, Gail L. Brown has authored 41 papers receiving a total of 469 indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Molecular Biology, 13 papers in Oncology and 11 papers in Hematology. Recurrent topics in Gail L. Brown's work include Glutathione Transferases and Polymorphisms (14 papers), Myeloproliferative Neoplasms: Diagnosis and Treatment (9 papers) and Acute Myeloid Leukemia Research (8 papers). Gail L. Brown is often cited by papers focused on Glutathione Transferases and Polymorphisms (14 papers), Myeloproliferative Neoplasms: Diagnosis and Treatment (9 papers) and Acute Myeloid Leukemia Research (8 papers). Gail L. Brown collaborates with scholars based in United States, Australia and United Kingdom. Gail L. Brown's co-authors include James Keck, Azra Raza, Naomi Galili, Marsha Jones, Lisa Meng, Donna Greenberg, Scott E. Smith, Ralph V. Boccia, Alan F. List and John E. Godwin and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Cancer.

In The Last Decade

Gail L. Brown

41 papers receiving 454 citations

Peers

Countries citing papers authored by Gail L. Brown

Since Specialization

Citations

This map shows the geographic impact of Gail L. Brown's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Gail L. Brown with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Gail L. Brown more than expected).

Fields of papers citing papers by Gail L. Brown

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Gail L. Brown. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Gail L. Brown. The network helps show where Gail L. Brown may publish in the future.

Co-authorship network of co-authors of Gail L. Brown

This figure shows the co-authorship network connecting the top 25 collaborators of Gail L. Brown. A scholar is included among the top collaborators of Gail L. Brown based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Gail L. Brown. Gail L. Brown is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Immunologic and objective tumor responses to PEGylated human IL-10 (AM0010) with 5-FU/LV and oxaliplatin (FOLFOX) in metastatic pancreatic adenocarcinoma (PDAC) 2017 ·Annals of Oncology ·(unknown), Aung Naing, Gerald S. Falchook, Manish R. Patel, Jeffrey R. Infante, Raid Aljumaily, (unknown), Karen A. Autio, Zev A. Wainberg, Milind Javle, Johanna C. Bendell, Shubham Pant, Annie Hung, Peter Van Vlasselaer, Gail L. Brown, Martin Oft, Kyriakos P. Papadopoulos	1
2	PEGylated human IL-10 (AM0010) in combination with pembrolizumab in anti-PD1 and CTLA-4 refractory melanoma. 2017 ·Journal of Clinical Oncology ·Aung Naing, Deborah Jean Lee Wong, Jeffrey R. Infante, Manish R. Patel, Shubham Pant, Bartosz Chmielowski, Filip Jankú, Coya Tapia, Navneet Ratti, Peter Van Vlasselaer, Gail L. Brown, Annie Hung, Martin Oft, Adi Diab	3
3	Anti-tumor activity of PEGylated human IL-10 (AM0010) in renal cancer alone and in combination with anti-PD1 2016 ·Annals of Oncology ·Aung Naing, K. Papadopoulos, Karen A. Autio, Patrick A. Ott, Manish R. Patel, Deborah J. Wong, Gerald S. Falchook, Shubham Pant, (unknown), Drew Rasco, Amita Patnaik, Johanna C. Bendell, Todd M. Bauer, Rivka R. Colen, David S. Hong, Peter Van Vlasselaer, Gail L. Brown, Martin Oft, (unknown), Jeffrey R. Infante	1
4	Phase 1 dose-ranging study of ezatiostat hydrochloride in combination with lenalidomide in patients with non-deletion (5q) low to intermediate-1 risk myelodysplastic syndrome (MDS) 2012 ·Journal of Hematology & Oncology ·Azra Raza, Naomi Galili, Deborah Mulford, Scott E. Smith, Gail L. Brown, David P. Steensma, Roger M. Lyons, Ralph V. Boccia, Mikkael A. Sekeres, Guillermo Garcia‐Manero, Ruben A. Mesa	20
5	Prediction of response to therapy with ezatiostat in lower risk myelodysplastic syndrome 2012 ·Journal of Hematology & Oncology ·Naomi Galili, Pablo Tamayo, Olga Botvinnik, Jill P. Mesirov, (unknown), Gail L. Brown, Azra Raza	18
6	Oral ezatiostat HCl (Telintra®, TLK199) and Idiopathic Chronic Neutropenia (ICN): a case report of complete response of a patient with G-CSF resistant ICN following treatment with ezatiostat, a glutathione S-transferase P1-1 (GSTP1-1) inhibitor 2011 ·Journal of Hematology & Oncology ·Roger M. Lyons, Sharon Wilks, (unknown), Gail L. Brown	18
7	A phase 2 randomized multicenter study of 2 extended dosing schedules of oral ezatiostat in low to intermediate‐1 risk myelodysplastic syndrome 2011 ·Cancer ·Azra Raza, Naomi Galili, Scott E. Smith, John E. Godwin, Ralph V. Boccia, Han Myint, Daruka Mahadevan, Deborah Mulford, Mark U. Rarick, Gail L. Brown, Dale Schaar, Stefan Faderl, Rami S. Komrokji, Alan F. List, Mikkael A. Sekeres	36
8	Randomized Phase III Study of Canfosfamide in Combination With Pegylated Liposomal Doxorubicin Compared With Pegylated Liposomal Doxorubicin Alone in Platinum-Resistant Ovarian Cancer 2010 ·International Journal of Gynecological Cancer ·Ignace Vergote, Neil J. Finkler, James B. Hall, O.O. Melnyk, Robert P. Edwards, Marsha Jones, James Keck, Lisa Meng, Gail L. Brown, Elaine M. Rankin, James J. Burke, Ralph V. Boccia, Carolyn D. Runowicz, Peter G. Rose	47
9	Phase 2 study of canfosfamide in combination with pegylated liposomal doxorubicin in platinum and paclitaxel refractory or resistant epithelial ovarian cancer 2010 ·Journal of Hematology & Oncology ·John J. Kavanagh, Charles F. Levenback, Pedro T. Ramírez, (unknown), (unknown), Marsha Jones, Lisa Meng, Gail L. Brown, Robert C. Bast	21
10	Phase 2 Randomized Multicenter Study of Extended Dosing Schedules of Oral Ezatiostat HCl (Telintra), a Glutathione Analog Prodrug GSTP1-1 Inhibitor, In Low to Intermediate-1 Risk Myelodysplastic Syndrome (MDS) 2010 ·Blood ·Azra Raza, Naomi Galili, Scott E. Smith, John E. Godwin, Ralph V. Boccia, Han Myint, Daruka Mahadevan, Deborah Mulford, Mark U. Rarick, Mary Ann Allison, O.O. Melnyk, Lisa Meng, Marsha Jones, Gail L. Brown, (unknown), Mikkael A. Sekeres	2
11	Phase 1-2a Multicenter Dose-Ranging Study of Canfosfamide in Combination with Carboplatin and Paclitaxel as First-Line Therapy for Patients with Advanced Non-small Cell Lung Cancer 2009 ·Journal of Thoracic Oncology ·Lecia V. Sequist, Panos Fidias, Jennifer S. Temel, Tatjana Kolevska, Michael S. Rabin, Ralph V. Boccia, Howard A. Burris, Robert J. Belt, Mark S. Huberman, O.O. Melnyk, Glenn Mills, (unknown), D. Caldwell, James Keck, Lisa Meng, Marsha Jones, Gail L. Brown, Martin J. Edelman, Thomas J. Lynch	18
12	Phase 1-2a multicenter dose-escalation study of ezatiostat hydrochloride liposomes for injection (Telintra®, TLK199), a novel glutathione analog prodrug in patients with myelodysplastic syndrome 2009 ·Journal of Hematology & Oncology ·Azra Raza, Naomi Galili, Natalie S. Callander, Leonel Ochoa, Lawrence D. Piro, Peter D. Emanuel, Stephanie Williams, Howard A. Burris, Stefan Faderl, Zeev Estrov, Peter Curtin, Richard A. Larson, James Keck, Marsha Jones, Lisa Meng, Gail L. Brown	49
13	Single agent, canfosfamide (C, TLK286) vs pegylated liposomal doxorubicin (D) or topotecan (T) in 3rd-line treatment of platinum (P) refractory or resistant ovarian cancer (OC): Phase 3 study results 2007 ·Journal of Clinical Oncology ·I. Vergote, N. Finkler, (unknown), Alfredo Löhr, (unknown), Daniela Matei, David R. Spriggs, J. J. Kavanagh, Jan B. Vermorken, Gail L. Brown, S.B. Kaye	19
14	Phase I-II trial of TLK286, a novel glutathione analog prodrug, in combination with carboplatin (C) and paclitaxel (P) as first-line treatment for advanced non-small cell lung cancer (NSCLC) 2005 ·Journal of Clinical Oncology ·Lecia V. Sequist, P. Fidias, Jennifer S. Temel, (unknown), Patricia Ostler, Michael S. Rabin, Mark S. Huberman, (unknown), Gail L. Brown, Thomas J. Lynch	2
15	Synergistic effect of TELCYTA™ (TLK286) in combination with paclitaxel, doxorubicin, carboplatin, oxaliplatin, cisplatin, docetaxel, gemcitabine and iressa in human cancer cells. 2004 ·Cancer Research ·Hua Xu, (unknown), (unknown), Gail L. Brown, James Keck	7
16	Phase 1 Study of TLK286 (Telcyta) Administered Weekly in Advanced Malignancies 2004 ·Clinical Cancer Research ·Lee S. Rosen, (unknown), (unknown), L. F. Wiggins, James Keck, (unknown), (unknown), Kiran Patel, Gail L. Brown	26
17	TLK286-induced activation of the stress response apoptotic signaling pathway 2002 ·Fangfang Meng, (unknown), Gail L. Brown, James Keck, W. David Henner, (unknown), R.F. Gomez, M. Wick	6
18	Phase 1 dose optimization study for V-echinocandin 2000 ·Gail L. Brown, (unknown), Jörg Täubel	5
19	Carnitine in dried blood spots: a method suitable for neonatal screening 1991 ·Clinica Chimica Acta ·(unknown), Francis Bowling, Gail L. Brown, Alan Clague, Alison Thompson	11
20	Environmental deprivation and transient elevation of sweat electrolytes 1985 ·The Journal of Pediatrics ·(unknown), John D. Lloyd‐Still, Gail L. Brown, Harry Shwachman	10

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact